U.S. Parathyroid Disorders Market Size, Share & Forecast 2026–2032

ID: MR-11782 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Parathyroid Disorders Market
  • ✓Market Size 2024: USD 1.42 billion
  • ✓Market Size 2032: USD 2.26 billion
  • ✓CAGR: 6.0%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Dialysis Formularies Set Share: Amgen's Parsabiv and Sensipar sit inside the ESRD bundled payment system, where DaVita and Fresenius Medical Care control purchasing volume. Their formulary committees, rather than prescriber preference, decide which calcimimetic captures secondary hyperparathyroidism share.
FINDING 02
Hypoparathyroidism Drives Premium Competition: Conventional calcium and calcitriol remain the default standard, yet Ascendis Pharma's Yorvipath, FDA-approved in August 2024, is redefining hypoparathyroidism as a branded, once-daily hormone replacement category. Generics will not dominate this niche, because rare-disease payers reward durability over price.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Ambulatory Surgery Contracts: Medical device and diagnostics suppliers should secure intraoperative PTH assay and nerve-monitoring contracts with ambulatory surgical centers before the end of 2026, because outpatient parathyroidectomy volume is migrating from hospital operating rooms to lower-cost sites where procurement is consolidating.

Competitive Overview of Parathyroid Disorders in the U.S.

The U.S. parathyroid disorders market is moderately concentrated in branded therapeutics and highly fragmented in diagnostics and surgery. Amgen leads calcimimetics through Sensipar and Parsabiv, while Ascendis Pharma and AstraZeneca compete for the rare hypoparathyroidism niche following AstraZeneca's acquisition of Amolyt Pharma. Generic cinacalcet from Teva Pharmaceuticals and Viatris has compressed prices materially since patent expiry, reshaping margins across the category.

Domestic companies hold structural advantages because purchasing decisions run through U.S. reimbursement channels. Competitive advantage depends on access to Medicare Part D and ESRD bundled payment formularies, relationships with nephrology groups and endocrine surgery centers, and the capacity to fund orphan-drug clinical programs. International entrants without U.S. medical affairs infrastructure face long adoption cycles, so most share gains accrue to companies already embedded in dialysis and endocrinology prescribing networks.

Demand Drivers Shaping Parathyroid Disorder Care in the U.S.

The first driver is the expanding end-stage renal disease population, which the United States Renal Data System reports above 800,000 patients receiving dialysis. Secondary hyperparathyroidism affects most of this cohort, so calcimimetic and active vitamin D volumes scale with dialysis census. Amgen benefits most through Parsabiv, while Teva Pharmaceuticals and Viatris capture volume in generic cinacalcet through formulary substitution by dialysis organizations.

The second driver is rising detection of primary hyperparathyroidism in adults over 60, fueled by routine calcium panels ordered in primary care. Surgical parathyroidectomy and minimally invasive procedures expand accordingly, favoring Medtronic and Stryker, whose intraoperative monitoring tools support focused exploration. The third driver is the approval of long-acting parathyroid hormone replacement, specifically Ascendis Pharma's Yorvipath, which shifts competition toward dosing durability and patient quality-of-life outcomes.

Competitive Restraints and Market Challenges

Price competition is the most immediate constraint. Generic cinacalcet from Teva Pharmaceuticals and Viatris has driven net prices down sharply since patent expiry, forcing Amgen to defend Sensipar through contracting and dialysis bundle positioning rather than list price. Medicare drug price negotiation under the Inflation Reduction Act adds further pressure on branded calcimimetics. Diagnostic laboratories face similar margin compression as Abbott, Roche Diagnostics and Siemens Healthineers bundle intact PTH assays into broader immunoassay contracts.

Talent and infrastructure gaps limit competitive reach. Endocrine surgery capacity is concentrated in academic medical centers in the Northeast, Midwest and California, leaving rural patients dependent on referral chains that delay parathyroidectomy. Compliance costs under FDA quality system requirements and CLIA certification raise entry thresholds for smaller diagnostic and device firms, reinforcing the advantage of established suppliers such as Medtronic and Stryker.

Growth Opportunities for Market Players

The most underserved opportunity lies in hypoparathyroidism, where conventional therapy has long required multiple daily calcium and active vitamin D doses. Ascendis Pharma is targeting this gap with Yorvipath, while AstraZeneca is advancing eneboparatide through its Amolyt acquisition to compete for the same patient population. Early entrants with payer contracts for rare-disease coverage will hold share before 2030.

Ambulatory migration creates a second opening. Outpatient parathyroidectomy and focused intraoperative PTH monitoring favor suppliers that bundle assays, disposables and surgeon training, a space where Medtronic, Stryker and Siemens Healthineers can each offer integrated kits. Laboratory operators such as Quest Diagnostics and LabCorp can extend PTH testing into primary care screening programs targeting adults over 60.

Market at a Glance

MetricDetail
Market Size 2024USD 1.42 billion
Market Size 2032USD 2.26 billion
Growth Rate (CAGR)6.0%
Most Critical Decision FactorPayer formulary access across dialysis and Medicare Part D
Largest RegionSouthern United States
Competitive StructureConcentrated in branded therapeutics, fragmented in diagnostics and surgery

Leading Market Participants

  • Amgen
  • Ascendis Pharma
  • AstraZeneca
  • Teva Pharmaceuticals
  • Viatris
  • Medtronic
  • Stryker
  • Roche Diagnostics
  • Abbott
  • Siemens Healthineers

Regulatory and Policy Environment

The FDA governs therapeutic approvals, and the Orphan Drug Act grants seven years of market exclusivity to hypoparathyroidism treatments, which shapes the competitive window for Ascendis Pharma and AstraZeneca. The Hatch-Waxman Act defines generic entry for cinacalcet, while FDA 510(k) clearance governs intraoperative PTH monitoring devices used by Medtronic and Stryker. CLIA certification determines which laboratories can run PTH assays, affecting Abbott, Roche Diagnostics and Siemens Healthineers.

The CMS ESRD Prospective Payment System bundles calcimimetics and vitamin D analogs into dialysis payments, making dialysis organizations the decisive purchasers. Medicare Part D coverage and the Inflation Reduction Act negotiation framework determine net pricing for branded drugs. The Anti-Kickback Statute constrains manufacturer engagement with nephrology and endocrinology prescribers, pushing companies toward compliant medical education and evidence-based promotion.

Competitive Outlook for Parathyroid Disorders in the U.S.

By 2032, the competitive structure will shift toward greater consolidation among dialysis purchasers, with DaVita and Fresenius Medical Care exerting more control over calcimimetic selection. Generic cinacalcet from Teva Pharmaceuticals and Viatris will hold the majority of volume, leaving Amgen to defend Parsabiv on clinical differentiation and bundled contracting terms.

Rare-disease competition will intensify as Ascendis Pharma and AstraZeneca establish branded hypoparathyroidism franchises. Surgical and diagnostic segments will remain fragmented, but suppliers offering integrated intraoperative monitoring and assay platforms will consolidate share among Medtronic, Stryker, Abbott and Siemens Healthineers.

Frequently Asked Questions

Amgen leads calcimimetic therapy through Sensipar and Parsabiv, particularly in dialysis settings. Ascendis Pharma and AstraZeneca are building positions in hypoparathyroidism.
Teva Pharmaceuticals and Viatris have driven significant price erosion in generic cinacalcet since patent expiry. This forces branded players to compete on contracting and clinical differentiation.
Calcimimetics and vitamin D analogs are reimbursed through the ESRD bundled payment system, making dialysis operators the key purchasers. Their formulary decisions often determine which product captures share.
Medtronic and Stryker compete in intraoperative PTH monitoring and surgical tools used during parathyroidectomy. Growth in ambulatory surgical settings is making procurement more consolidated and contract-driven.
Access to payer contracts and orphan-drug exclusivity provides the strongest early advantage in hypoparathyroidism. Entrants without U.S. medical affairs and reimbursement infrastructure face prolonged adoption timelines.

Market Segmentation

By Disorder Type
  • Hypoparathyroidism
  • Primary Hyperparathyroidism
  • Secondary Hyperparathyroidism
  • Tertiary Hyperparathyroidism
By Treatment Type
  • Calcimimetics
  • PTH Analogs
  • Active Vitamin D Analogs
  • Parathyroidectomy Procedures
By End User
  • Dialysis Organizations
  • Hospitals
  • Endocrinology Clinics
  • Ambulatory Surgical Centers

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Parathyroid Disorders Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Disorder Type Insights
4.1 Hypoparathyroidism
4.2 Primary Hyperparathyroidism
4.3 Secondary Hyperparathyroidism
4.4 Tertiary Hyperparathyroidism
4.5 Others
Chapter 05 Treatment Type Insights
5.1 Calcimimetics
5.2 PTH Analogs
5.3 Active Vitamin D Analogs
5.4 Parathyroidectomy Procedures
5.5 Others
Chapter 06 End User Insights
6.1 Dialysis Organizations
6.2 Hospitals
6.3 Endocrinology Clinics
6.4 Ambulatory Surgical Centers
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Amgen
7.2.2 Ascendis Pharma
7.2.3 AstraZeneca
7.2.4 Teva Pharmaceuticals
7.2.5 Viatris
7.2.6 Medtronic
7.2.7 Stryker
7.2.8 Roche Diagnostics
7.2.9 Abbott
7.2.10 Siemens Healthineers
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.